GlassScriptPhysician profile
Averie Giles
NPI 1649644642
$9,181.69
in general payments reported to CMS, 2019-2025
32 companies · $2,454 in 2025
The $2,454 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $2,787 · 2023: $1,961 · 2024: $1,979 · 2025: $2,454.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,032 · Travel and Lodging: $254 · Education: $108.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,032.30 |
| Travel and Lodging | $253.93 |
| Education | $108.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $3,045.79 | 2022-2025 | Synchromedii, Intellis Adaptivestim, Vanta Adaptivestim |
| Abbott Laboratories | $941.67 | 2022-2025 | Proclaim, Eterna, Exclaim |
| Collegium Pharmaceutical, INC. | $828.97 | 2022-2025 | Xtampza, Belbuca |
| Boston Scientific Corporation | $610.40 | 2022-2025 | Wavewriter Alpha Prime 16, Superion Indirect Decompression System, Intracept |
| Nevro Corp. | $463.45 | 2022-2024 | Senza |
| Globus Medical, INC. | $366.75 | 2025 | Senza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $302.64 | 2022-2025 | Relistor |
| Biotronik Nro, INC. | $297.65 | 2024-2025 | Prospera |
| Grt US Holding, INC. | $246.84 | 2022 | |
| Tersera Therapeutics LLC | $226.25 | 2022-2025 | Prialt |
| Nalu Medical, INC. | $212.43 | 2023-2024 | Nalu Neurostimulation System |
| Relievant Medsystems, INC. | $211.55 | 2023 | Intracept |
| Mml US, INC. | $200.44 | 2023-2025 | Reactiv8 |
| Ibsa Pharma INC. | $144.97 | 2022-2025 | Licart, Tirosint, Tirosint |
| Stryker Corporation | $129.44 | 2024 | Mild Device Kit |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated | $129.23 | 2025 | |
| Averitas Pharma INC. | $128.16 | 2023-2025 | Qutenza |
| Abbvie INC. | $126.56 | 2023 | |
| Vertos Medical, INC. | $115.06 | 2024 | Mild Device Kit |
| Idorsia Pharmaceuticals US INC | $93.74 | 2023 | Quviviq |
| Spinal Simplicity, LLC | $86.77 | 2022-2023 | Ha Minuteman G3-R |
| Pacira Pharmaceuticals Incorporated | $36.41 | 2023 | Zilretta, Iovera |
| Pfizer INC. | $36.23 | 2023 | |
| Metacel Pharmaceuticals LLC | $28.22 | 2022-2023 | Ozobax |
| Hikma Pharmaceuticals USA | $26.33 | 2022 | |
| Bioventus LLC | $25.74 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $22.41 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $21.70 | 2022 | |
| Fidia Pharma USA INC. | $20.52 | 2024 | Hymovis |
| Kyowa Kirin, INC. | $19.96 | 2024 | Crysvita |
| Kowa Pharmaceuticals America, INC. | $18.56 | 2022 | |
| Spr Therapeutics, INC | $16.85 | 2025 | Sprint Pns System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Averie Giles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.